Wu Qing-Li, Fu Yun-Feng, Zhou Wen-Liang, Wang Jun-Xia, Feng Yong-Hong, Liu Jing, Xu Jian-Yi, He Pei-Lan, Zhou Ru, Tang Wei, Wang Gui-Feng, Zhou Yu, Yang Yi-Fu, Ding Jian, Li Xiao-Yu, Chen Xiao-Ru, Yuan Chong, Lawson Brian R, Zuo Jian-Ping
Laboratory of Immunopharmacology and State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.
J Pharmacol Exp Ther. 2005 May;313(2):705-11. doi: 10.1124/jpet.104.080416. Epub 2005 Jan 7.
Lymphocytes depend on transmethylation reactions for efficient activation and function. These reactions are primarily catalyzed by S-adenosylmethionine-dependent methyltransferases, which convert S-adenosylmethionine to S-adenosyl-L-homocysteine. S-adenosyl-L-homocysteine is then hydrolyzed by S-adenosyl-L-homocysteine hydrolase to prevent feedback inhibition of transmethylation reactions. By impeding S-adenosyl-L-homocysteine hydrolase, a build-up of S-adenosyl-L-homocysteine occurs, and most intracellular transmethylation reactions cease. Thus, a nontoxic inhibitor of this enzyme might be a useful immunosuppressive therapeutic agent. We identified a potent reversible type III inhibitor of S-adenosyl-L-homocysteine hydrolase, DZ2002 [methyl 4-(adenin-9-yl)-2-hydroxybutanoate], and determined its cytotoxic and immunologic effects. We demonstrated that DZ2002 blocked S-adenosyl-L-homocysteine hydrolase more effectively than a type I inhibitor, but cytotoxicity from DZ2002 was greatly reduced. Although DZ2002 did not prevent concanavalin A-induced T cell proliferation or interleukin (IL)-2 production, it significantly reduced both a mixed lymphocyte reaction and IL-12 production from in vitro-stimulated splenocytes. In addition, levels of CD80 and CD86 on human monocytic THP-1 cells were decreased in a dose-dependent manner in the presence of 0.1 to 10 microM DZ2002, and decreases were also seen in IL-12 and tumor necrosis factor-alpha production from both mouse thioglycollate-stimulated peritoneal macrophages and THP-1 cells. In vivo, DZ2002 significantly suppressed a delayed-type hypersensitivity reaction as well as antibody secretion. We conclude that DZ2002's immunosuppressive effects are likely not solely attributed to T cell inhibition but also to the obstruction of macrophage activation and function through reductions in cytokine output and/or T cell costimulation. These data suggest an important dual role for the S-adenosyl-l-homocysteine hydrolase in both macrophage and T cell function.
淋巴细胞的有效激活和功能依赖于转甲基反应。这些反应主要由依赖S-腺苷甲硫氨酸的甲基转移酶催化,该酶将S-腺苷甲硫氨酸转化为S-腺苷-L-高半胱氨酸。然后,S-腺苷-L-高半胱氨酸被S-腺苷-L-高半胱氨酸水解酶水解,以防止对转甲基反应的反馈抑制。通过抑制S-腺苷-L-高半胱氨酸水解酶,会导致S-腺苷-L-高半胱氨酸积累,大多数细胞内转甲基反应停止。因此,这种酶的无毒抑制剂可能是一种有用的免疫抑制治疗药物。我们鉴定出一种有效的S-腺苷-L-高半胱氨酸水解酶可逆性III型抑制剂DZ2002 [4-(腺嘌呤-9-基)-2-羟基丁酸甲酯],并确定了其细胞毒性和免疫学效应。我们证明,DZ2002比I型抑制剂更有效地阻断S-腺苷-L-高半胱氨酸水解酶,但DZ2002的细胞毒性大大降低。虽然DZ2002不能阻止伴刀豆球蛋白A诱导的T细胞增殖或白细胞介素(IL)-2的产生,但它显著降低了混合淋巴细胞反应以及体外刺激的脾细胞产生的IL-12。此外,在存在0.1至10 microM DZ2002的情况下,人单核细胞THP-1细胞上CD80和CD86的水平呈剂量依赖性降低,并且从小鼠巯基乙酸盐刺激的腹腔巨噬细胞和THP-1细胞产生的IL-12和肿瘤坏死因子-α也有所降低。在体内,DZ2002显著抑制迟发型超敏反应以及抗体分泌。我们得出结论,DZ2002的免疫抑制作用可能不仅归因于T细胞抑制,还归因于通过降低细胞因子输出和/或T细胞共刺激来阻碍巨噬细胞的激活和功能。这些数据表明S-腺苷-L-高半胱氨酸水解酶在巨噬细胞和T细胞功能中具有重要的双重作用。